- The companies and academics are working to assess challenges and seek opportunities that could influence Scleroderma R&D. The therapies under development are focused on novel approaches to treat/improve Scleroderma.
The “Scleroderma – Pipeline Insight, 2021” drug pipelines have been added to ResearchAndMarkets.com’s offering.
This report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in the Scleroderma pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
A scleroderma is a group of rare diseases that involve the hardening and tightening of the skin and connective tissues. Scleroderma affects women more often than men and most commonly occurs between the ages of 30 and 50. While there is no cure for scleroderma, a variety of treatments can ease symptoms and improve quality of life. There are many different types of scleroderma. In some people, scleroderma affects only the skin. But in many people, scleroderma also harms structures beyond the skin, such as blood vessels, internal organs, and the digestive tract (systemic scleroderma). Scleroderma results from an overproduction and accumulation of collagen in body tissues. There are 2 main types of scleroderma: localized scleroderma – just affects the skin and systemic sclerosis – may affect blood circulation and internal organs as well as the skin.
The report by the publisher outlays comprehensive insights of the present scenario and growth prospects across the indication. A detailed picture of the Scleroderma pipeline landscape is provided which includes the disease overview and Scleroderma treatment guidelines. The assessment part of the report embraces, a depth Scleroderma commercial assessment and clinical assessment of the pipeline products under development. In the report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Scleroderma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: Businesswire
